Pharma finds a way to gain weight
In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
Approaching datasets for big pharma
J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts.
UCB leads the stale scale
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Lilly gambles on Dice
Lilly follows others into the oral autoimmune space, not long after its leader questioned the future of small molecules.
Car-T beyond cancer? Novartis and others say yes
Putting Car-T therapy to work in autoimmune diseases has caught the attention of several biotech and big pharma groups.